Liu Kangsheng, Xu Zhirong, Mao Xiaodong, Li Taiping, Wen Juan
Department of Clinical Laboratory, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital Nanjing 210029, China.
Department of Clinical Laboratory, The First Affiliated Hospital of Soochow University Suzhou 215006, China.
Am J Transl Res. 2020 Oct 15;12(10):6763-6774. eCollection 2020.
COVID-19 (Coronavirus disease 2019) epidemic has rapidly spread since its outbreak. By 24:00, July 19, China had reported 83,682 confirmed infectious cases of COVID-19, including 4,634 deaths. The prevention and control of COVID-19 remains extremely urgent. Owing to its strong infectivity and onset in populations, early detection of infectious cases of COVID-19 is of great significance to control the epidemic. Nevertheless, clinical experiences in nucleic acid testing (NAT) are limited. False negative results of NAT inconsistent with clinical diagnosis are often reported. Therefore, it is necessary to improve the sensitivity and specificity of NAT. This study aims to summarize the current situation and prospect of NAT application based on the lasted findings on COVID-19 infection. Meanwhile, potential methods are proposed to improve the validity of NAT, like improving sample quality. The review may provide references for clinical and experimental explorations on COVID-19.
新型冠状病毒肺炎（COVID-19）疫情自爆发以来迅速蔓延。截至7月19日24时，中国累计报告新型冠状病毒肺炎确诊病例83682例，其中死亡4634例。新型冠状病毒肺炎的防控形势依然极为严峻。由于其强大的传染性及人群易感性，早期发现新型冠状病毒肺炎感染病例对于控制疫情具有重要意义。然而，核酸检测（NAT）的临床经验有限。经常有核酸检测结果为假阴性且与临床诊断不符的报告。因此，有必要提高核酸检测的敏感性和特异性。本研究旨在基于新型冠状病毒肺炎感染的最新研究结果总结核酸检测应用的现状与前景。同时，提出了提高核酸检测有效性的潜在方法，如提高样本质量。本综述可为新型冠状病毒肺炎的临床及实验探索提供参考。
